Competition Law and Patents
A Follow-on Innovation Perspective in the Biopharmaceutical Industry

Irina Haracoglou
Attorney at Law, Independent Researcher/Consultant

NEW HORIZONS IN COMPETITION LAW AND ECONOMICS

Edward Elgar
Cheltenham, UK • Northampton, MA, USA
PART I: THE PROBLEM – ACCESS AS A NECESSARY ELEMENT OF FOLLOW-ON INNOVATION?

1. Biopharmaceutical R&D: the increased importance of cumulative innovation and related concerns 3
   1.1 Introduction 3
   1.2 The case of research tools 7
      1.2.1 Defining research tools 7
      1.2.2 The patent experience in biotechnology: biomedical research tools 9
      1.2.3 The effect of patent trends on the patent balance for research tools 12
   1.3 Conclusion 16

PART II: THE PATENT BALANCE AND WORKING SOLUTIONS IN THE PATENT SYSTEM

2. The patent system as a system of balancing 21
   2.1 The Patent Balance 21
   2.2 The particular importance of the patent balance in the biopharmaceutical industry 25
      2.2.1 The patent system and the biopharmaceutical industry 25
      2.2.1.1 Biopharmaceutical innovation and patenting 28
      2.2.1.2 Has the importance of patents been overstated? 31
   2.3 Conclusion 34

3. The patent system and some potential safety nets 36
   3.1 Introduction to the patent safety nets 36
3.2 The patent safety nets
   3.2.1 Experimental use exemption
      3.2.1.1 The experimental use exemption: a viable and effective working solution? 39
      3.2.1.2 The US experience: a helpful paradigm? 44
      3.2.1.3 Conclusion on the EUE 46
   3.2.2 The reverse doctrine of equivalents and blocking patents 48
   3.2.3 Patent pools 51
   3.2.4 Compulsory licensing in the patent provisions 54
      3.2.4.1 Introduction to compulsory licensing 54
         (a) Definition and history 54
         (b) Support and opposition for CL 54
         (c) Grounds for granting a compulsory licence 57
      3.2.4.2 Analysis of the role of CL 58
         (a) The role of CL in balancing commensurability 58
            (i) CL as a mechanism to induce broad licensing 58
            (ii) CL for non-use 59
            (iii) CL for significant technological advances 59
            (iv) CL to address health emergencies 61
            (v) CL as a remedy for anti-competitive conduct 63
         (b) Conclusions on CL 63

4. The right to health as an interpretive principle of patent law 70
   4.1 Introduction 70
   4.2 The right to health as a human right and its status in European law 71
      4.2.1 Introduction to the right to health 71
      4.2.2 Sources of the right to health 74
      4.2.3 Implications of the right to health 76
         4.2.3.1 Elements of the right to health 77
         4.2.3.2 Obligation to respect, protect and fulfil 79
      4.2.4 International Efforts to Strengthen the Right to Health 80
   4.3 The right to health and patent law: The fundamental nature of health concerns and the move towards a right to health as an interpretive principle in patent law 82
PART III: ANTITRUST AS A COMPLEMENT TO THE PATENT SYSTEM

5. Unilateral conduct, intellectual property rights and Competition Law: a systems’ interaction
   5.1 Introduction
   5.2 The practice of the courts
      5.2.1 The existence/exercise distinction
   5.3 IPRs and competition: A systems’ interaction
      5.3.1 IPRs – public goods, exclusivity and information goods
         5.3.1.1 Public goods and market failure
         5.3.1.2 Patronage, procurement and property
      5.3.2 Implications for competition
         5.3.2.1 IP like other property rights for the purposes of competition
         5.3.2.2 Competition embedded in the IP system
         5.3.2.3 The transition from separate to unified fields
         5.3.2.4 How antitrust control affects incentives to innovate
      5.3.3 Recent recognition of antitrust control
   5.4 Conclusions
6. The Duty to Deal under Art. 82 EC
   6.1 Introduction
      6.1.1 What is a refusal to deal and what is the rationale behind its prohibition?
      6.1.2 Concerns relating to a refusal to deal: Potential harm to competition
   6.2 The state of the law
      6.2.1 Cutting off existing customers: The dependence cases
      6.2.2 'Reservation of an ancillary activity' and leverage economics
      6.2.3 The indispensability requirement and the essential facilities doctrine (EFD)
         6.2.3.1 Indispensability
         6.2.3.2 Two-market requirement
         6.2.3.3 Objective justification
      6.2.4 New product innovation
   6.3 Conclusions

Appendix The refusal to deal cases under Art. 82

PART IV: A MORE INNOVATION SENSITIVE APPROACH TO THE INTERFACE OF COMPETITION LAW AND PATENTS?

7. The duty to deal as applied to address technology access problems in the biopharmaceutical industry
   7.1 Conclusions on the patent system in the case of research tools
      7.1.1 The particularity of research tools: pre-commercial stage patents
      7.1.2 A gap in the patent system?
      7.1.3 The more the better? Optimal market structure for innovation
   7.2 Two possible avenues for increased access to essential research tools
      7.2.1 Patent law
      7.2.2 A role for Art. 82?
         7.2.2.1 Indispensability
         7.2.2.2 Preventing the emergence of a new product for which there is potential consumer demand
         7.2.2.3 Elimination of competition on a downstream or neighbouring market/two-market requirement